GlaxoSmithKline Plc has entered into a cancer collaboration with Merck KGaA of Germany which features a direct challenge to Keytruda’s (pembrolizumab) dominant position in lung cancer. Announced on 5 February, the partnership involves the co-development and commercialisation of the Merck asset M7824 (bintrafusp alfa) which is an investigational bifunctional fusion protein immunotherapy.
